Piperacillin sodium, CAS 59703-84-3, is the monosodium salt of (2S,5R,6R)-6-{[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, with a molecular weight of 539.54 g/mol and a molecular formula of C23H26N5NaO7S. The sterile pharma grade is supplied as a white to off-white lyophilized or crystalline powder intended for aseptic formulation into injectable dosage forms; when a validated oral formulation is required, the same grade may be incorporated into tablets, capsules, or granules with enteric protection. The product model is designated as sterile API grade for parenteral and oral use, with microbial limits, endotoxin burden, particle control, and residual solvent profile more restrictive than those applied to non-sterile or research-grade piperacillin sodium.

Release testing follows the applicable USP and Ph. Eur. monographs. Water content is determined by Karl Fischer titration according to USP <921> Method Ic; a parenteral-grade lot is typically controlled at ≤ 2.0% w/w to reduce hydrolysis during storage. The pH of a 10% w/v aqueous solution at 25°C is measured by USP <791>, with the accepted band typically 5.0–7.5. Related substances are resolved by reverse-phase HPLC against the official reference standard, with total impurities held at NMT 2.0% and unspecified individual impurities at NMT 0.10% for the sterile parenteral profile. Residual solvents comply with USP <467>; when present, Class 3 solvents are limited to ≤ 0.5% w/w, and Class 2 solvents are evaluated against Option 1 limits. Bacterial endotoxin testing uses Limulus amebocyte lysate per USP <85>, and a conservative internal release limit of ≤ 0.050 EU/mg is commonly applied for high-dose infusion use. Sterility is established by membrane filtration per USP <71> with not less than 14 days of incubation. The model-specific release record therefore includes simultaneous chemical and microbiological certification; a lot is not transferred to sterile packaging without both profile acceptance and a controlled bioburden result prior to aseptic fill.

Aseptic processing of the sterile API is performed in a Grade A or ISO Class 5 zone per ISO 14644-1:2015 and EU GMP Annex 1. Terminal sterilization by steam is not used because the beta-lactam ring undergoes hydrolysis at autoclave temperatures; gamma irradiation is similarly avoided because radiolytic cleavage yields colored degradation products and measurable potency loss. The powder is therefore obtained either by lyophilization from a sterile-filtered solution or by aseptic crystallization from a controlled solvent system. For lyophilized material, secondary drying is performed at shelf temperatures not exceeding 25°C after primary drying below the collapse temperature, with final chamber pressure below 100 µbar. Aseptic crystallization in 316L stainless steel equipment with 0.2 µm hydrophobic vent filtration is typical for lots intended for dry powder fill. The powder is discharged into gamma-sterilized low-density polyethylene liners within aluminium foil pouches containing desiccant, and the pouch is sealed under nitrogen. The moisture vapor barrier of the container closure system is selected to minimize water uptake during storage at 2–8°C.

Environmental monitoring in aseptic powder handling zones includes active air sampling, settle plates, and contact plates. Under EU GMP Annex 1, Grade A zones are expected to show <1 CFU/m³ in active air samples and <1 CFU/plate for settle plates over a 4 h exposure; Grade B support zones are controlled at <10 CFU/m³. These values are not product-specific but define the operational framework for sterile API packaging. The fill line for sterile powder may use a gravimetric or flow-dependent dosing head installed in a restricted access barrier system or isolator; the equipment is sterilized by vaporized hydrogen peroxide before each campaign. Dosing head contact parts are made of 316L stainless steel or pharmaceutical-grade polymer, and the fill weight tolerance for a 1 g vial is typically held to ± 5% of the target mass. After filling, vials are stoppered under slight vacuum or nitrogen overlay to reduce oxygen exposure.

What Limits Direct Oral Administration of Piperacillin Sodium?

Piperacillin sodium is acid-labile; unprotected exposure to simulated gastric fluid at pH 1.2 and 37°C produces rapid beta-lactam ring opening, and the resulting oral bioavailability is insufficient for reliable systemic therapy in most published human and veterinary assessments. Published data for this specific oral configuration are limited, but the observed degradation pattern is consistent with acid-catalyzed hydrolysis of the four-membered beta-lactam ring. Therefore, oral tablet, capsule, and granule products require enteric coating or equivalent gastro-resistant protection with release pH thresholds above 5.5. Acid resistance testing in 0.1 N HCl for 2 h followed by buffered release at pH 6.8 phosphate buffer per USP <711> is a minimum in vitro control for such dosage forms. Direct compression of sterile piperacillin sodium without granulation is not recommended because the powder exhibits poor flow, low bulk density, and caking at relative humidity above 60%. Processing humidity is generally maintained between 40% and 50% RH, with material temperature below 25°C, to preserve granule friability and avoid sticking on tablet tooling.

Moisture uptake at relative humidity above 60% not only causes caking but also increases free water availability, which accelerates hydrolysis. The pH of a partially hydrolyzed sample shifts toward acidic, reducing solubility and increasing the risk of further degradation. For dry granulation or direct encapsulation, the API moisture content should remain below 2.0% w/w before processing; if the powder is exposed for more than 30 min at more than 60% RH, it should be retested for water content and impurity profile before use.

Sterile Injection Formulation: Reconstitution, Stability, and Incompatibility Boundaries

For injectable products, reconstitution is usually performed to 200 mg/mL with Water for Injection or 0.9% w/v sodium chloride. The resulting solution may be clear to pale yellow; a pronounced yellow or amber color indicates degradation and should not be used. In-use stability is established per the finished product monograph, but common clinical handlings limit diluted infusion solutions to 24 h at room temperature or 48 h at 2–8°C. The solution is not mixed with aminoglycoside antibiotics such as gentamicin, tobramycin, or amikacin in the same intravenous line because covalent inactivation of the aminoglycoside can occur in prolonged contact conditions. Concomitant administration is performed through separate accesses with a saline flush. Sodium bicarbonate and other alkaline solutions are incompatible because beta-lactam hydrolysis accelerates above pH 8.0.

The bacterial endotoxin limit for the sterile API is derived from the K/M calculation used in USP <85>. For a maximum adult dose of 4 g in a 70 kg patient, M is 57.1 mg/kg, and K is 5 EU/kg, giving a calculated limit of 0.0875 EU/mg. The internal threshold of ≤ 0.050 EU/mg applies a safety margin below this value and is more restrictive than the calculation requires for most adult intravenous regimens. For neonatal or pediatric formulations, the assigned limit must be recalculated based on the actual maximum dose in the target population.

Spectrum and Handling Contrast with Ampicillin, Amoxicillin, and Piperacillin/Tazobactam

Piperacillin sodium is a ureidopenicillin, containing a 4-ethyl-2,3-dioxopiperazine carbonyl substituent that enhances penetration through certain Gram-negative outer membrane porins and provides activity against Pseudomonas aeruginosa, whereas ampicillin and amoxicillin are amino penicillins with little clinically relevant P. aeruginosa cover. Piperacillin sodium remains susceptible to hydrolysis by many class A extended-spectrum beta-lactamases, class C AmpC cephalosporinases, and carbapenemases. The formulated combination piperacillin/tazobactam in 8:1 w/w ratio adds tazobactam sodium to inhibit susceptible class A beta-lactamases and improves empirical cover in mixed environments. The single-component sterile API has the advantage of simpler supply chain quality control because there is no fixed-dose ratio to verify, but its use in beta-lactamase-rich settings requires susceptibility confirmation.

Compared with amoxicillin trihydrate, piperacillin sodium has inferior oral bioavailability and markedly greater hygroscopicity, so it is not a substitute for conventional oral amoxicillin in routine outpatient therapy. Compared with ampicillin sodium, the powder has a broader Gram-negative spectrum but places stricter demands on moisture control during processing. Non-sterile piperacillin sodium may be supplied for research or environmental fate studies, with higher bioburden and no sterility or endotoxin release testing; the sterile pharma grade uses the same chemical synthesis but adds aseptic final crystallization or lyophilization and complete microbiological release testing.

When Piperacillin Sodium Is Selected for Oral Granule or Capsule Dosage Forms

Piperacillin sodium is not a first-line oral beta-lactam, but the same sterile API can be used in specialized oral granule or capsule formulations when the target site of action justifies the risk of low systemic availability, or when the product is intended for niche veterinary or clinical investigation. Granulation is performed in a high-shear granulator with dry binders such as microcrystalline cellulose and crospovidone, followed by wet massing with povidone in an isopropanol-water system. The wet mass is extruded through a screen of 1.0 mm and dried in a fluidized-bed dryer with inlet air temperature no higher than 45°C; higher inlet temperatures risk localized dehydration and chemical degradation. Roller compaction is preferred over slugging because the sterile powder sticks to steel tooling when humidity exceeds 60% RH. An enteric coating is applied in a Wurster or side-spray fluidized bed; the coating thickness is tuned to pass acid resistance in 0.1 N HCl for 2 h and to release not less than 80% of the drug in pH 6.8 phosphate buffer within 45 min per USP <711>. The finished granules may be filled into hard gelatin capsules or sachets; however, the moisture content of the gelatin shell and the granule must be equilibrated to avoid shell embrittlement or softening.

Because piperacillin sodium is hygroscopic and acid-labile, an oral formulation cannot rely solely on an enteric polymer. The core may require a pH-modifying excipient to maintain local pH below the degradation threshold during release. In vitro release tests do not establish bioequivalence; a pharmacokinetic study in the target species is required. Published data for this specific piperacillin sodium oral dosage form are limited, so scale-up batches require real-time degradation and dissolution monitoring under ICH Q1A conditions. The oral route should not be assumed to provide predictable systemic exposure from this API without formulation-specific bioavailability data.

Upon release, every sterile API lot is accompanied by a certificate of analysis that carries the lot number, manufacturing date, retest date, and individual value for each specification parameter. The manufacturing site operates under ICH Q7 and applicable national current good manufacturing practice; aseptic operations follow 21 CFR 211.42 and EU GMP Annex 1. Change control, deviation management, and batch disposition follow 21 CFR 211.160 and 211.165. Because the API is used in injectable final products, the absence of endotoxin and sterility testing failures is part of the release decision, not a post-release confirmation. Material stored in unopened foil pouches at 2–8°C is generally assigned a retest period based on long-term stability data; opened containers are used immediately or requalified for moisture and microbiological attributes. The sterile API is not repackaged outside a classified environment because moisture and bioburden excursions can violate the sterile grade designation.